Funder
Medicinski Fakultet, Sveučilište u Zagrebu
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference31 articles.
1. Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE et al (2020) Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA 324:2292–2300
2. Reis G, dos Santos Moreira-Silva EA, Medeiros Silva DC, Thabane L, Cruz Milagres A et al (2022) Effect of early treatment with fluvoxamine on risk of emergeny care and hospitalizations among patients with COVID-19: the TOGETHER randomized platform trial. Lancet Glob Health 10:e42-51. https://doi.org/10.1016/S2214-109X(21)00448-4
3. Lenze E. Fluvoxamine for early treatment of COVID-19: a fully-remote, randomized placebo controlled trial. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04668950. Accessed 26 Sept 2022
4. Seo H, Kim H, Bae S, Park S, Chung H, Sung HS et al (2022) Fluvoxamine treatment of patients with symptomatic COVID-19 in a community treatment center: a preliminary result of randomized controlled trial. Infect Chemother 54:102–113
5. Bramante CT, Juling JD, Tignanelli CJ, Buse JB, Liebovitz DM, Nicklas JM et al (2022) Randomized trial of metformin, ivermectin and fluvoxamine for Covid-19. N Engl J Med 387:599–610
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献